Recently Featured

Kailera makes history with record-breaking $625m IPO

April 20, 2026
Kailera Therapeutics has successfully completed a landmark initial public offering (IPO), raising $625 million to advance its clinical pipeline. This substantial funding will enable the biotech firm to propel its lead candidate, ribupatide, through late-stage trials for both oral and injectable formulations targeting obesity. The significant capital influx marks a pivotal moment for Kailera, positioning…

Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool

April 20, 2026
Lilly’s obesity medication, Foundayo, has made a significant impact in the market, with analysts reporting approximately 1,390 prescriptions written within just two days of its launch. This rapid uptake underscores the growing demand for effective obesity treatments as healthcare providers increasingly recognize the importance of addressing this chronic condition. The swift adoption of Foundayo not…

FDA Considers Expanding Testosterone Therapy Indications for Libido Enhancement

April 20, 2026
The U.S. Food and Drug Administration (FDA) is reportedly evaluating the potential expansion of testosterone therapy indications to include enhancement of libido in men. This consideration arises from growing evidence suggesting that testosterone levels significantly influence sexual desire and overall quality of life. As the FDA weighs this decision, it highlights an evolving understanding of…

Ongoing Cases